BioNTech SE (BNTX)
Summary
BNTX Chart
BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down
BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.
BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More
BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. BNTX's next-gen anti-CTLA-4 gotistobart and PD-L1xVEGF-A bispecific antibody pumitamig have multiple pivotal trial catalysts, with key data readouts expected at WCLC 2026. COMIRNATY's XFG variant expansion provides near-term revenue, but COVID-19 vaccine sales face competitive and demand headwinds, reflected in lowered 2026 guidance.
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech SE (BNTX) Q2 2026 Earnings Call Transcript
BioNTech SE Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 4 | $380.8 | $364.76 | -$16.04 | -4.21% |
 Dodge & Cox Dodge & Cox Funds | 3.68M | $368.7M | $341.06M | -$27.64M | -7.5% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 67 | $6,609.54 | $6,217.6 | -$391.94 | -5.93% |
| NA Nizar Araji National Bank Of Canada /FI/ | 1,325 | $130,592.94 | $124,119.37 | -$6,473.57 | -4.96% |
| CD Carine Duboscq Groupama Asset Managment | 184,775 | $18.14M | $17.2M | -$934,793.75 | -5.15% |
BioNTech SE (BNTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioNTech SE ever had a stock split?
BioNTech SE Profile
| Biotechnology Industry | Healthcare Sector | Ugur Sahin CEO | NASDAQ (NGS) Exchange | 09075V102 CUSIP |
| DE Country | 7,807 Employees | 2 Jun 2022 Last Dividend | - Last Split | - IPO Date |
Overview
BioNTech SE is a pioneering biotechnology company that specializes in developing and commercializing innovative immunotherapies for combating cancer and various infectious diseases. Established in 2008, the company has been at the forefront of leveraging cutting-edge scientific research to devise treatments that enhance the immune system's ability to fight serious illnesses. BioNTech's approach encompasses a wide range of product candidates in different stages of clinical trials, aiming to address the unmet medical needs in oncology and infectious diseases. Operating out of Mainz, Germany, BioNTech has established a global footprint through strategic collaborations and partnerships with leading pharmaceutical companies and organizations, including Genentech, Inc., Sanofi S.A., Pfizer Inc., and others, to strengthen and expedite vaccine development and delivery worldwide.
Products and Services
BioNTech SE’s portfolio is rich with innovative product candidates and services targeting a variety of cancers and infectious diseases. Their focus predominantly lies within oncology, aiming to provide novel treatments for patients worldwide. Below are some of their key developmental projects:
- FixVac Candidates: A series including BNT111 for advanced melanoma, BNT112 for prostate cancer, BNT113 for HPV16+ head and neck cancers, BNT114 for triple negative breast cancer, BNT115 in ovarian cancer, and BNT116 for non-small cell lung cancer. These products are in various phases of clinical trials, showcasing BioNTech’s broad-spectrum approach towards cancer immunotherapy.
- BNT122: Targeted for first-line melanoma and multiple solid tumors, it is currently undergoing Phase II and I clinical trials.
- BNT131 - BNT142: These are early-stage clinical trial candidates for treating multiple solid tumors, reflecting the company's commitment to expanding its oncology pipeline.
- BNT151 - BNT153: In development stages for solid tumors, with ongoing research to validate their effectiveness.
- BNT211: A candidate for multiple solid tumors, indicating the versatility of BioNTech’s research in addressing different cancer types.
- BNT221: For pancreatic and other cancers, furthering the company's reach into highly challenging and aggressive cancer types.
- BNT311, BNT312, and ONC-392: Focused on metastatic non-small cell lung cancer and multiple solid tumors, with BNT311 and BNT312 in various stages of clinical trials and ONC-392 in a Phase III clinical trial for ovarian cancer.
- BNT321: An IgG1 monoclonal antibody being explored for pancreatic cancer in a Phase I clinical trial.
- BNT411: A small molecule immunomodulator for solid tumors, currently in early phase testing.
- Prophylactic Vaccines: For infectious diseases such as shingles, malaria, tuberculosis, HSV-2, among others, demonstrating BioNTech’s capability beyond oncology into preventing widespread infectious diseases.
Furthermore, BioNTech’s strategic partnerships, including with the Coalition for Epidemic Preparedness Innovations (CEPI), aim to enrich the mRNA vaccine ecosystem in Africa, showcasing its dedication to global health improvements and innovative vaccine development.
